InsidersTradesSigma
Follow the abrdn Life Sciences Investors stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €96.2m. The latest transaction was reported on 20 July 2026 (Acquisition). Among the most active insiders: Saba Capital Management, L.P.. Every trade is free.
55
Insider Decl.
n/a
Thresholds
€6m
26 ops.
Buy Volume
€5m
29 ops.
Sell Volume
25Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,570 of 29,063 companies
75.0
score / 100
Value82
Quality68
FCF yld28%
Earn yld5.6%
EV/EBITDA·
ROE3.1%
Gross mgn·
Net mgn76%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 July 2026
Declarations55 total
527 shares@ US$19.920.016% mcap100.0% of flowCommon StockSEC:0001104659-26-085027:0
Canonical exit: 14 Oct 2026 (T+90)
7,923 shares@ US$16.8818100.0% of flowCommon StockSEC:0001104659-25-122394:0
Canonical exit: 16 Mar 2026 (T+90)
6,989 shares@ US$14.100.8% of flowCommon StockSEC:0001510281-25-000498:0
24,328 shares@ US$13.992.7% of flowCommon StockSEC:0001510281-25-000492:0
700 shares@ US$14.130.1% of flowCommon StockSEC:0001510281-25-000488:0
15,116 shares@ US$14.281.8% of flowCommon StockSEC:0001510281-25-000481:0
14,083 shares@ US$14.041.7% of flowCommon StockSEC:0001510281-25-000449:0
23,723 shares@ US$13.892.8% of flowCommon StockSEC:0001510281-25-000436:0
400 shares@ US$13.830.0% of flowCommon StockSEC:0001510281-25-000435:0
10,710 shares@ US$14.071.3% of flowCommon StockSEC:0001510281-25-000428:0
11,419 shares@ US$12.711.3% of flowCommon StockSEC:0001510281-25-000325:0
23,729 shares@ US$12.082.7% of flowCommon StockSEC:0001510281-25-000315:0
730 shares@ US$12.280.1% of flowCommon StockSEC:0001510281-25-000308:0
12,689 shares@ US$11.981.4% of flowCommon StockSEC:0001510281-25-000291:0
1,366 shares@ US$12.190.2% of flowCommon StockSEC:0001510281-25-000287:0
9,144 shares@ US$11.781.0% of flowCommon StockSEC:0001510281-25-000226:0
1,700 shares@ US$11.920.2% of flowCommon StockSEC:0001510281-25-000219:0
15,400 shares@ US$11.671.6% of flowCommon StockSEC:0001510281-25-000211:0
30,156 shares@ US$11.143.1% of flowCommon StockSEC:0001510281-25-000204:0
10,321 shares@ US$12.231.2% of flowCommon StockSEC:0001510281-25-000186:0
17,621 shares@ US$12.452.1% of flowCommon StockSEC:0001510281-25-000178:0
48,623 shares@ US$12.585.9% of flowCommon StockSEC:0001510281-25-000176:0
32,922 shares@ US$13.014.1% of flowCommon StockSEC:0001510281-25-000174:0
2,329 shares@ US$13.210.3% of flowCommon StockSEC:0001510281-25-000167:0
200 shares@ US$13.620.0% of flowCommon StockSEC:0001510281-25-000113:0
25 of 55 declarations
关于 abrdn Life Sciences Investors
abrdn Life Sciences Investors 是一家专注于生命科学领域的投资公司。它旨在通过投资该领域的创新公司来创造回报。